Abstract | OBJECTIVES: METHODS: This retrospective study included clinical data from 40 patients who underwent regular follow-up at our institution in June 2013. Among these patients, 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. RESULTS: The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 patients. Ten patients with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p < 0.01). Among these 10 patients, 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 patients after starting TCZ was significantly higher than that of all 40 patients after the initial treatments (100% and 67% at 12 months, respectively; p = 0.03). CONCLUSIONS: TCZ effectively prevented relapses of AOSD, and it resolved the disease activity.
|
Authors | Naoshi Nishina, Yuko Kaneko, Hideto Kameda, Tsutomu Takeuchi |
Journal | Modern rheumatology
(Mod Rheumatol)
Vol. 25
Issue 3
Pg. 401-4
(May 2015)
ISSN: 1439-7609 [Electronic] England |
PMID | 25401229
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- tocilizumab
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Retrospective Studies
- Secondary Prevention
- Still's Disease, Adult-Onset
(drug therapy, prevention & control)
- Treatment Outcome
|